- Home
- BDTX vs FCNCP Comparison
BDTX vs FCNCP Comparison
Compare BDTX & FCNCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | FCNCP |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | N/A |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | BDTX | FCNCP |
|---|---|---|
| Price | $1.90 | $18.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 512.0K | 12.5K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ 97.95 |
| Revenue | N/A | ★ $9,541,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.19 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $18.84 |
| 52 Week High | $4.94 | $22.60 |
Technical Indicators
Market Signals| Indicator | BDTX | FCNCP |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 24.31 |
| Support Level | $1.76 | N/A |
| Resistance Level | $2.28 | $20.64 |
| Average True Range (ATR) | 0.08 | 0.30 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 16.48 | 1.83 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About FCNCP First Citizens BancShares Inc.
First Citizens is a US regional bank with total assets of around $237 billion as of June 30, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing in 2025.